On January 3, 2024 G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, reported that G1’s Chief Executive Officer Jack Bailey will provide a corporate presentation during the 42nd Annual J.P. Morgan Healthcare Conference on January 10, 2024, at 1:30 PM PST (Press release, G1 Therapeutics, JAN 3, 2024, View Source [SID1234638909]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The webcast of the event will be accessible on the Events & Presentations page of View Source

On January 3, 2024 CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, reported that members of its senior management team will present at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024, at 2:15 p.m. PT in San Francisco (Press release, CRISPR Therapeutics, JAN 3, 2024, View Source [SID1234638908]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the fireside chat will be available on the "Events & Presentations" page in the Investors section of the Company’s website at View Source A replay of the webcast will be archived on the Company’s website for 14 days following the presentation.

On January 3, 2024 Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) reported that Scott Struthers, Ph.D., founder and chief executive officer of Crinetics, will present at the 42nd Annual J.P. Morgan Healthcare Conference, which is taking place in San Francisco, CA from January 8-11, 2024 (Press release, Crinetics Pharmaceuticals, JAN 3, 2024, View Source [SID1234638907]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details of the corporate presentation are as follows:

Date: Tuesday, January 9, 2024

Time: 3:45 p.m. Pacific Time

Room: Borgia Room

The live and archived webcast will be accessible on the Events & Presentations page in the Investors section on the Crinetics’ website at www.crinetics.com/events.

If you are interested in arranging a 1×1 meeting with management, please contact your J.P. Morgan representative.

On January 3, 2024 Coherus BioSciences, Inc. ("Coherus," Nasdaq: CHRS), reported that senior management will present at the upcoming 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024, at 9:45 a.m. Pacific Time (Press release, Coherus Biosciences, JAN 3, 2024, View Source [SID1234638906]). The presentation and Q&A session will be accessible via Webcast through a link posted on the Investor Events Calendar section of the Coherus website: View Source This webcast will be available for replay until February 9, 2024.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On January 3, 2024 Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, reported that it will host a call detailing top-line data from its pivotal trial of iopofosine I 131 in Waldenstrom’s macroglobulinemia on Monday, January 8, 2024 at 8:00 am ET (Press release, Cellectar Biosciences, JAN 3, 2024, View Source [SID1234638905]). The company will also be presenting at the Biotech Showcase conference the following day. Details for each event are as follows:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Top-line Conference call details:
Date: Monday, January 8, 2024
Time: 8:00 am ET / 5:00 am PT
Dial-in: 1-888-886-7786
Webcast Link: Click HERE

Biotech Showcase Presentation
Date: Tuesday, January 9, 2024
Time: 5:00 pm ET / 2:00 pm PT
Location: Hilton San Francisco Union Square
Webcast: Click HERE
A replay of both the conference call and Biotech Showcase presentation will be available on the investor’s portion of the company’s website.